文献速递妇科

低级别子宫内膜间质肉瘤中卵巢切除术与激素抑制的影响:一项多中心回顾性研究

Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review.
PubMed 文献 · Gynecol Oncol · 2018-03-11

该多中心回顾性研究评估了辅助激素抑制(HT)联合或不联合双侧卵巢切除术(BSO)对低级别子宫内膜间质肉瘤(LG-ESS)患者无进展生存期(PFS)和总生存期(OS)的影响,共纳入112例手术患者,其中59例有术后随访数据。结果显示BSO组PFS为38个月 vs 保留卵巢组11个月(p=0.071),HT组PFS为28个月 vs 无HT组23个月(p=0.77)。作者认为结果支持BSO延长PFS,但受样本量限制,需要更大样本和更完整随访的研究来确定辅助激素抑制的效果。

要点

  • BSO组PFS为38个月 vs 保留卵巢组11个月(p=0.071),差异未达统计学显著。
  • HT组PFS为28个月 vs 无HT组23个月(p=0.77),差异无统计学意义。
  • 全组中位PFS为53个月,中位OS为63个月。

核心结论

  • 与既往系列一致,本研究结果支持BSO可延长LG-ESS患者的PFS,但受样本量限制。
  • 需要更大样本和更完整随访的研究来确定辅助激素抑制的效果。

研究设计与样本

  • 多机构回顾性综述,纳入1985年至2014年接受治疗的低级别LG-ESS患者。
  • 从医疗记录中提取人口学、治疗和复发数据,病理诊断由妇科病理学家确认。
  • 通过邮寄调查获得长期患者报告结局。
  • 112例患者接受LG-ESS手术,其中59例有术后数据,中位随访55个月(范围1-325个月)。
  • 诊断时平均年龄48.5岁(范围22-82岁)。

主要发现

  • 49例(61%)为I期疾病。
  • 最常见症状为异常子宫出血(38%)和盆腔包块(17%)。
  • 71例(63%)在诊断时接受BSO。
  • 在59例有术后随访信息的患者中,49例(73%)接受BSO,26例(44%)接受HT,20例(33%)接受期待管理,6例(10%)接受化疗、放疗或两者。
  • 全组中位PFS为53个月,中位OS为63个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 样本量有限。
  • 需要更大样本和更完整随访的研究来确定辅助激素抑制的效果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Low grade endometrial stromal sarcoma (LG-ESS) is a rare cancer with an indolent course. We aimed to assess the effectiveness of adjuvant hormonal suppression (HT) with or without oophorectomy (BSO) in prolonging progression free survival (PFS) and overall survival (OS) in patients with LG-ESS. METHODS: We performed a multi-institutional retrospective review of patients treated for low grade LG-ESS from 1985 to 2014. Demographics, treatment and recurrence data were abstracted from medical records. Pathologic diagnosis was confirmed by a gynecologic pathologist. Long-term patient-reported outcomes were obtained via mailed survey. RESULTS: One-hundred-twelve patients underwent surgery for LG-ESS; 59 had postoperative data with a median follow-up of 55months (1-325months). The mean age at diagnosis was 48.5years (22-82years). Forty-nine (61%) had stage I disease. The most common presenting symptoms were abnormal uterine bleeding (38%) and pelvic mass (17%). Seventy-one (63%) patients had BSO at the time of diagnosis. Of the 59 patients with postoperative follow-up information, 49 (73%) underwent BSO, 26 (44%) received HT, 20 (33%) were expectantly managed, and 6 (10%) received chemotherapy, radiation or both. Median PFS for the entire group was 53months and OS was 63months. PFS for those who underwent BSO compared with those who retained their ovaries was 38 vs 11months, p=0.071. PFS for HT vs no HT was 28 vs 23months, p=0.77. CONCLUSIONS: Consistent with prior series, our results support BSO to prolong PFS in LG-ESS but are limited by sample size. Larger studies with more complete follow-up are needed to determine the effect of adjuvant hormonal suppression.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Stewart LE, Beck TL, Giannakopoulos NV, et al. Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review. Gynecol Oncol. 2018. PMID: 29534832. doi:10.1016/j.ygyno.2018.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。